Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity
Open Access
- 20 March 2014
- journal article
- Published by American Society of Hematology in Blood
- Vol. 123 (12), 1957-1960
- https://doi.org/10.1182/blood-2014-01-547869
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytesBlood, 2013
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaThe New England Journal of Medicine, 2013
- CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodiesBlood, 2011
- Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritisNature Chemical Biology, 2010
- Differential Regulation of Human NK Cell-Mediated Cytotoxicity by the Tyrosine Kinase ItkThe Journal of Immunology, 2007
- From the bench to the bedside: ways to improve rituximab efficacyBlood, 2004